CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives

EP: 1.The Rationale for CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

EP: 2.The Impact of CAR T-Cell Therapy on Relapsed/Refractory MM Treatment

EP: 3.How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment

EP: 4.Key Takeaways from the CARTITUDE-1 and KarMMa Studies

Now Viewing

EP: 5.CAR T-Cell Therapy in R/R MM: Treatment Selection, Safety, and Future Perspectives

EP: 6.Insights from CARTITUDE-4 and KarMMa-3 in R/R MM

EP: 7.Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM

Video content above is prompted by the following questions:

• Can you describe the ideal patient to receive cilta-cel vs ide-cel?
  • In which patient populations would you not choose to give cilta-cel? Ide-cel?
  • What is the role of patient preferences and shared decision-making when choosing between cilta-cel and ide-cel?

• How does the safety profile factor into your treatment choice?
  • What are the some commonly observed toxicities with CAR T-cell therapy?
  • What are some strategies used to manage adverse events?

• What are some challenges or barriers seen with CAR T-cell therapy?
  • What are the logistical challenges associated with CAR T-cell therapy and what are the potential solutions?

• What is the future of CAR T-cell therapy in relapsed/refractory multiple myeloma (R/R MM)?
  • Please highlight any other trials of note investigating the use of cilta-cel or ide-cel for R/R MM.
  • What other targets or dual targets are being investigated? (GPRC5D, CD19, BCMA, etc)